At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 92 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 7, 2021·Updated Jun 10, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Osteoarthritis and Spinal Arthritis. Currently recruiting, targeting 92 participants across 2 sites in 2 countries.
Detailed Summary
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Spinal Arthritis
CountriesAntigua and Barbuda, Greece
Collaborators--
Timeline
Phase 1Recruiting
2022202320242025202620272028
First PostedDec 2021
Enrollment StartDec 2022
TodayJul 2026
Primary CompletionDec 2027
First PostedDec 7, 2021
Enrollment StartDec 1, 2022
Primary CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 5 yearsPosted 4.6 years agoPrimary completion in 1.4 years
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells